1. Home
  2. EXAS vs HSIC Comparison

EXAS vs HSIC Comparison

Compare EXAS & HSIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXAS
  • HSIC
  • Stock Information
  • Founded
  • EXAS 1995
  • HSIC 1932
  • Country
  • EXAS United States
  • HSIC United States
  • Employees
  • EXAS N/A
  • HSIC N/A
  • Industry
  • EXAS Medical Specialities
  • HSIC Medical Specialities
  • Sector
  • EXAS Health Care
  • HSIC Health Care
  • Exchange
  • EXAS Nasdaq
  • HSIC Nasdaq
  • Market Cap
  • EXAS 10.7B
  • HSIC 9.0B
  • IPO Year
  • EXAS N/A
  • HSIC 1995
  • Fundamental
  • Price
  • EXAS $51.91
  • HSIC $73.42
  • Analyst Decision
  • EXAS Strong Buy
  • HSIC Buy
  • Analyst Count
  • EXAS 20
  • HSIC 10
  • Target Price
  • EXAS $70.26
  • HSIC $79.70
  • AVG Volume (30 Days)
  • EXAS 2.8M
  • HSIC 1.6M
  • Earning Date
  • EXAS 07-30-2025
  • HSIC 08-05-2025
  • Dividend Yield
  • EXAS N/A
  • HSIC N/A
  • EPS Growth
  • EXAS N/A
  • HSIC 8.11
  • EPS
  • EXAS N/A
  • HSIC 3.21
  • Revenue
  • EXAS $2,828,128,000.00
  • HSIC $12,669,000,000.00
  • Revenue This Year
  • EXAS $14.58
  • HSIC $4.28
  • Revenue Next Year
  • EXAS $12.75
  • HSIC $3.57
  • P/E Ratio
  • EXAS N/A
  • HSIC $22.88
  • Revenue Growth
  • EXAS 11.57
  • HSIC 1.75
  • 52 Week Low
  • EXAS $39.97
  • HSIC $60.56
  • 52 Week High
  • EXAS $72.83
  • HSIC $82.49
  • Technical
  • Relative Strength Index (RSI)
  • EXAS 44.34
  • HSIC 55.47
  • Support Level
  • EXAS $52.00
  • HSIC $73.02
  • Resistance Level
  • EXAS $55.90
  • HSIC $75.76
  • Average True Range (ATR)
  • EXAS 2.31
  • HSIC 1.36
  • MACD
  • EXAS -0.04
  • HSIC -0.01
  • Stochastic Oscillator
  • EXAS 24.90
  • HSIC 52.24

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

About HSIC Henry Schein Inc.

Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are global Distribution and Value-Added Services; global Specialty Products; and global Technology. It generates the majority of its revenue from the global Distribution and Value-Added Services segment which includes distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.

Share on Social Networks: